Brentuximab Vedotin Demonstrates Significant Activity in B-Cell Lymphoma
the Cancer Therapy Advisor take:
According to a new study published in the journal Blood, researchers from various institutions across the United States have found that brentuximab vedotin has significant activity in patients with refractory diffuse large B-cell lymphoma (DLBCL) and a variety of CD30 expression levels.
For the open-label, phase 2 study, researchers sought to investigate the efficacy of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL), and in this planned subset analysis, researchers included 49 patients with DLBCL and 19 patients with other B-cell NHLs.
Results showed an objective response rate of 44% for patients with DLBCL. Specifically, 17% achieved a complete remission with a median duration of 16.6 months as of this analysis.
Although all patients that experienced a response had quantifiable CD30 levels, researchers found no statistical correlation between objective response and CD30 expression level. In addition, patients with other B-cell NHLs also responsed to brentuximab vedotin (8 complete responses, 2 partial responses).
In regard to safety, observed adverse events were similar to known toxicities of the anti-CD30 antibody-drug conjugate. When brentuximab vedotin was used in combination with rituximab, similar activity was observed with a well tolerated safety profile.
Brentuximab vedotin has significant activity in patients with refractory diffuse large B-cell lymphoma.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival
- Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC
- Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer
- Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC